Oregon's experience with newborn screening for Fabry disease, Gaucher disease, Pompe disease and mucopolysaccharidosis type I

2021 ◽  
Vol 132 (2) ◽  
pp. S108
Author(s):  
Sarah Viall ◽  
Anna Dennis ◽  
Sara Denniston ◽  
Amy Yang
Keyword(s):  
Newborn Screening ◽  
Fabry Disease ◽  
Pompe Disease ◽  
Gaucher Disease ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I

scholarly journals Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction

2020 ◽  
Vol 6 (1) ◽  
pp. 2 ◽  
Author(s):  
Patricia L. Hall ◽  
Rossana Sanchez ◽  
Arthur F. Hagar ◽  
S. Caleb Jerris ◽  
Angela Wittenauer ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Pompe Disease ◽  
Late Onset ◽  
Screening Program ◽  
Molecular Testing ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Analytical Tools ◽  
Mps I

We conducted a pilot newborn screening (NBS) study for Pompe disease (PD) and mucopolysaccharidosis type I (MPS I) in the multiethnic population of Georgia. We screened 59,332 infants using a two-tier strategy of flow injection tandem mass spectrometry (FIA-MSMS) enzyme assays. The first tier of testing was a 2-plex assay measuring PD and MPS I enzyme activity, followed by a second-tier test with additional enzymes to improve specificity. Interpretation of results was performed using post-analytical tools created using Collaborative Laboratory Integrated Reports (CLIR). We identified a single case of infantile onset PD, two cases of late onset PD, and one pseudodeficiency. The positive predictive value (PPV) for PD screening during the study was 66.7%. No cases of MPS I were identified during the study period, but there were 2 confirmed cases of pseudodeficiency and 6 cases lost to follow up. The two-tier screening strategy was successful in reducing false positive results and allowed for the identification and early treatment of a case of infantile PD but the frequency of pseudodeficiency in MPS I is problematic. Molecular testing is required and should be covered by the screening program to avoid delays in case resolution.

The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening

2019 ◽  
Vol 211 ◽  
pp. 193-200.e2 ◽  
Author(s):  
Jennifer L. Taylor ◽  
Kristin Clinard ◽  
Cynthia M. Powell ◽  
Catherine Rehder ◽  
Sarah P. Young ◽  
...  
Keyword(s):  
North Carolina ◽  
Newborn Screening ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
The North

scholarly journals Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I

2020 ◽  
Vol 6 (1) ◽  
pp. 10 ◽  
Author(s):  
Dawn S. Peck ◽  
Jean M. Lacey ◽  
Amy L. White ◽  
Gisele Pino ◽  
April L. Studinski ◽  
...  
Keyword(s):  
Newborn Screening ◽  
False Positive ◽  
Dermatan Sulfate ◽  
False Positive Rate ◽  
False Negative ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Second Tier ◽  
Mps I

Enzyme-based newborn screening for Mucopolysaccharidosis type I (MPS I) has a high false-positive rate due to the prevalence of pseudodeficiency alleles, often resulting in unnecessary and costly follow up. The glycosaminoglycans (GAGs), dermatan sulfate (DS) and heparan sulfate (HS) are both substrates for α-l-iduronidase (IDUA). These GAGs are elevated in patients with MPS I and have been shown to be promising biomarkers for both primary and second-tier testing. Since February 2016, we have measured DS and HS in 1213 specimens submitted on infants at risk for MPS I based on newborn screening. Molecular correlation was available for 157 of the tested cases. Samples from infants with MPS I confirmed by IDUA molecular analysis all had significantly elevated levels of DS and HS compared to those with confirmed pseudodeficiency and/or heterozygosity. Analysis of our testing population and correlation with molecular results identified few discrepant outcomes and uncovered no evidence of false-negative cases. We have demonstrated that blood spot GAGs analysis accurately discriminates between patients with confirmed MPS I and false-positive cases due to pseudodeficiency or heterozygosity and increases the specificity of newborn screening for MPS I.

scholarly journals Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy

2019 ◽  
Vol 5 (2) ◽  
pp. 24 ◽  
Author(s):  
Alberto B. Burlina ◽  
Giulia Polo ◽  
Laura Rubert ◽  
Daniela Gueraldi ◽  
Chiara Cazzorla ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Lysosomal Storage Diseases ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Lysosomal Storage ◽  
Storage Diseases ◽  
Lysosomal Disorders ◽  
North Eastern ◽  
Second Tier

The increasing availability of treatments and the importance of early intervention have stimulated interest in newborn screening for lysosomal storage diseases. Since 2015, 112,446 newborns in North Eastern Italy have been screened for four lysosomal disorders—mucopolysaccharidosis type I and Pompe, Fabry and Gaucher diseases—using a multiplexed tandem mass spectrometry (MS/MS) assay system. We recalled 138 neonates (0.12%) for collection of a second dried blood spot. Low activity was confirmed in 62 (0.06%), who underwent confirmatory testing. Twenty-five neonates (0.02%) were true positive: eight with Pompe disease; seven with Gaucher disease; eight with Fabry disease; and two with Mucopolysaccharidosis type I. The combined incidence of the four disorders was 1 in 4497 births. Except for Pompe disease, a second-tier test was implemented. We conclude that newborn screening for multiple lysosomal storage diseases combined with a second-tier test can largely eliminate false-positives and achieve rapid diagnosis.

scholarly journals A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan

2013 ◽  
Vol 8 (1) ◽  
pp. 147 ◽  
Author(s):  
Shuan-Pei Lin ◽  
Hsiang-Yu Lin ◽  
Tuen-Jen Wang ◽  
Chia-Ying Chang ◽  
Chia-Hui Lin ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Screening Program ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Newborn Screening Program

scholarly journals Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management

2017 ◽  
Vol 182 ◽  
pp. 363-370 ◽  
Author(s):  
Lorne A. Clarke ◽  
Andrea M. Atherton ◽  
Barbara K. Burton ◽  
Debra L. Day-Salvatore ◽  
Paige Kaplan ◽  
...  
Keyword(s):  
Best Practices ◽  
Newborn Screening ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Diagnosis And Management

Genotype-phenotype correspondence in mucopolysaccharidosis type I and the implications for newborn screening

2018 ◽  
Vol 123 (2) ◽  
pp. S147
Author(s):  
Chester B. Whitley ◽  
Timothy J. Moss ◽  
Amy Gaviglio ◽  
Katie A. Wiens ◽  
Lynn Schema ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I
Sign in / Sign up

Export Citation Format

Share Document